In-vitro evaluation of the immunomodulatory effects of Baricitinib: Implication for COVID-19 therapy

•Baricitinib has been suggested as a promising therapy for COVID-19.•Baricitinib modulates in vitro SARS-CoV-2-specific-response in a whole blood platform.•Baricitinib decreases viral-specific-response mainly in mild/moderate COVID-19. Baricitinib seems a promising therapy for COVID-19. To fully-inv...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	The Journal of infection Ročník 82; číslo 4; s. 58 - 66
Hlavní autoři:	Petrone, Linda, Petruccioli, Elisa, Alonzi, Tonino, Vanini, Valentina, Cuzzi, Gilda, Najafi Fard, Saeid, Castilletti, Concetta, Palmieri, Fabrizio, Gualano, Gina, Vittozzi, Pietro, Nicastri, Emanuele, Lepore, Luciana, Grifoni, Alba, Antinori, Andrea, Vergori, Alessandra, Ippolito, Giuseppe, Cantini, Fabrizio, Goletti, Delia
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	England Elsevier Ltd 01.04.2021 The Authors. Published by Elsevier Ltd on behalf of The British Infection Association
Témata:	Azetidines Baricitinib COVID-19 COVID-19 Drug Treatment Cytokines Humans IGRA Purines Pyrazoles SARS-CoV-2 Specific immune-response Sulfonamides COVID-19 SARS-CoV-2 Specific immune-response Baricitinib IGRA
ISSN:	0163-4453, 1532-2742, 1532-2742
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!